NCT07417774
Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic
Enrolling by Invitation
Not specifiedAges 18+ObservationalNuvOx LLC
~40 participants
Updated 2026-02-18 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Tumor hypoxia biomarkers
Measured over until disease progression and up to 5 years
Conditions
Where it's being run
4 sites across 4 statesArizona1
Connecticut1
Missouri1
North Carolina1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subjects must be enrolled in the RESTORE study (NCT03862430) and provide written informed consent for the RESTORE LB sub-study
What this trial measures
- Tumor hypoxia biomarkersuntil disease progression and up to 5 years
Identify differentially expressed tumor hypoxia markers in newly-diagnosed glioblastoma subjects treated with NanO2 versus placebo in the RESTORE study.